BR112020004389A2 - composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. - Google Patents
composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. Download PDFInfo
- Publication number
- BR112020004389A2 BR112020004389A2 BR112020004389-3A BR112020004389A BR112020004389A2 BR 112020004389 A2 BR112020004389 A2 BR 112020004389A2 BR 112020004389 A BR112020004389 A BR 112020004389A BR 112020004389 A2 BR112020004389 A2 BR 112020004389A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- variant
- polypeptide
- fragment
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554605P | 2017-09-06 | 2017-09-06 | |
| US62/554,605 | 2017-09-06 | ||
| US201862652279P | 2018-04-03 | 2018-04-03 | |
| US62/652,279 | 2018-04-03 | ||
| PCT/US2018/049648 WO2019051015A1 (en) | 2017-09-06 | 2018-09-06 | VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020004389A2 true BR112020004389A2 (pt) | 2020-09-08 |
Family
ID=65517760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020004389-3A BR112020004389A2 (pt) | 2017-09-06 | 2018-09-06 | composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US20190070262A1 (OSRAM) |
| EP (1) | EP3678681A4 (OSRAM) |
| JP (2) | JP2020533301A (OSRAM) |
| KR (1) | KR20200066623A (OSRAM) |
| CN (1) | CN111315395A (OSRAM) |
| AU (2) | AU2018330444B2 (OSRAM) |
| BR (1) | BR112020004389A2 (OSRAM) |
| CA (1) | CA3080492A1 (OSRAM) |
| IL (2) | IL305370A (OSRAM) |
| MX (1) | MX2020002542A (OSRAM) |
| SG (1) | SG11202001384TA (OSRAM) |
| WO (1) | WO2019051015A1 (OSRAM) |
| ZA (1) | ZA202307212B (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| CN115667290A (zh) * | 2020-05-12 | 2023-01-31 | 再生元制药公司 | 新型il10激动剂及其使用方法 |
| US20220056091A1 (en) * | 2020-08-19 | 2022-02-24 | Bright Peak Therapeutics Ag | Modified il-18 polypeptides and uses thereof |
| KR20230117120A (ko) * | 2020-11-02 | 2023-08-07 | 심카 아이엘-18, 인크. | 인터류킨-18 변이체 및 사용 방법 |
| EP4293039A4 (en) * | 2021-02-10 | 2025-07-16 | Univ Nagasaki | NEW VARIANT OF HUMAN INTERLEUKIN-18 AND ITS USE |
| WO2023010021A1 (en) | 2021-07-27 | 2023-02-02 | Xencor, Inc. | Il-18-fc fusion proteins |
| JP2023024168A (ja) | 2021-08-06 | 2023-02-16 | 国立大学法人 長崎大学 | がんの治療剤 |
| WO2023114829A1 (en) * | 2021-12-15 | 2023-06-22 | Genentech, Inc. | Stabilized il-18 polypeptides and uses thereof |
| WO2023118497A1 (en) * | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| JP2025508826A (ja) * | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－１８ポリペプチド |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| JP2025508823A (ja) | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用 |
| MX2024011278A (es) | 2022-03-15 | 2024-09-25 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. |
| WO2023215834A1 (en) * | 2022-05-05 | 2023-11-09 | Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. | Methods for treating bladder cancer |
| KR20250046308A (ko) * | 2022-08-05 | 2025-04-02 | 퓨즈 바이오쎄라퓨틱스 아이엔씨. | Il-18 융합 단백질 및 il-18 생산 방법 |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| JP2025529313A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | Ｉｌ－１８バリアントポリペプチド |
| US20240209100A1 (en) * | 2022-10-21 | 2024-06-27 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| US20240166705A1 (en) * | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
| WO2024120489A1 (en) | 2022-12-07 | 2024-06-13 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug |
| IL321948A (en) | 2023-01-06 | 2025-09-01 | Lassen Therapeutics Inc | Anti-IL-18 BP antibodies |
| WO2024148241A1 (en) * | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
| CN120693345A (zh) * | 2023-01-06 | 2025-09-23 | 艾利妥 | 抗il18结合蛋白抗体及其使用方法 |
| AU2024211503A1 (en) * | 2023-01-24 | 2025-07-31 | Msd International Business Gmbh | Methods and compositions for combination therapy |
| WO2024251983A1 (en) * | 2023-06-09 | 2024-12-12 | Merck Patent Gmbh | Il-18 mimetics |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025015103A1 (en) * | 2023-07-10 | 2025-01-16 | The Children's Hospital Of Philadelphia | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology |
| US20250188166A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025068413A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025085447A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Pd-1 targeted il18-fc fusion proteins |
| CN120093897A (zh) * | 2023-12-04 | 2025-06-06 | 广州威溶特医药科技有限公司 | Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用 |
| CN120189493A (zh) | 2023-12-22 | 2025-06-24 | 广州威溶特医药科技有限公司 | Dr-18和m1病毒在制备抗肿瘤药物中的应用 |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025151273A1 (en) * | 2024-01-08 | 2025-07-17 | Adimab, Llc | Il-18 polypeptides and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025251226A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6790442B1 (en) | 1996-06-27 | 2004-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ |
| EP1669454A3 (en) * | 1996-06-27 | 2009-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| JP4024366B2 (ja) | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| JP3955352B2 (ja) * | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) * | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| JP2001266941A (ja) | 2000-03-17 | 2001-09-28 | Sony Corp | ゲル電解質電池の製造方法 |
| AU7516601A (en) * | 2000-06-02 | 2001-12-17 | Susan B Dillon | Methods of treating viral diseases with il-18 and il-18 combinations |
| ATE437234T1 (de) | 2000-06-15 | 2009-08-15 | Smithkline Beecham Corp | Verfahren zur herstellung eines physiologisch aktiven il-18 polypeptids |
| US6818444B2 (en) | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
| DE60208692T2 (de) | 2001-03-08 | 2006-07-13 | Ares Trading S.A. | Interleukin -18 mutantenproteine, deren herstellung und verwendung |
| CA2445049A1 (en) | 2001-05-04 | 2002-11-14 | Cornell Research Foundation, Inc. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| BR0206112A (pt) | 2001-10-10 | 2005-05-10 | Centocor Inc | Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina |
| US20040023336A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses |
| US6800479B2 (en) | 2001-12-11 | 2004-10-05 | Samyang Genex Corporation | Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them |
| DE60318014T2 (de) | 2002-01-07 | 2008-11-27 | Lifesensors, Inc. | Verfahren und zusammensetzungen für die proteinexpression und reinigung |
| US7220576B2 (en) | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| US7253260B2 (en) | 2002-04-17 | 2007-08-07 | Smithkline Beecham Corporation | Human IL-18 crystal structure |
| AU2003280017A1 (en) * | 2002-06-27 | 2004-01-19 | Smithkline Beecham Corporation | Methods of treating or preventing ibd with il-18 |
| WO2004032837A2 (en) * | 2002-10-08 | 2004-04-22 | Ares Trading S.A. | The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine |
| EP1613274B1 (en) * | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| ATE549353T1 (de) * | 2003-05-13 | 2012-03-15 | Merck Serono Sa | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen |
| US7655413B2 (en) | 2003-06-26 | 2010-02-02 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| ES2356154T3 (es) * | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| WO2005075648A1 (en) * | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
| CN101039696B (zh) | 2004-08-20 | 2011-08-17 | 史密丝克莱恩比彻姆公司 | 给药人il-18治疗创伤的方法 |
| WO2006073976A2 (en) | 2004-12-30 | 2006-07-13 | Lifesensors, Inc. | Compositions, methods, and kits for enhancing protein expression, solubility and isolation |
| JP2010503680A (ja) | 2006-09-14 | 2010-02-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヒトｉｌ−１８による調節ｔ細胞のモジュレーション |
| JP5469786B2 (ja) | 2006-12-29 | 2014-04-16 | ライフセンサーズ、インク． | タンパク質の発現増強および精製の方法および組成 |
| CN104888193A (zh) | 2007-11-07 | 2015-09-09 | 健泰科生物技术公司 | 用于治疗微生物病症的组合物和方法 |
| WO2009107458A1 (ja) | 2008-02-27 | 2009-09-03 | シャープ株式会社 | 照明装置、表示装置及びテレビ受信装置 |
| US8034910B2 (en) | 2008-05-06 | 2011-10-11 | Academia Sinica, Taiwan | SUMO fusion protein expression system for producing native proteins |
| CN101993495B (zh) | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| US9316417B2 (en) | 2012-06-29 | 2016-04-19 | Sunpower Corporation | Framing system for mounting solar collecting devices |
| CA2876099A1 (en) | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | Method for producing monomeric and multimeric molecules and uses thereof |
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| WO2015054386A1 (en) | 2013-10-08 | 2015-04-16 | Georgia State University Research Foundation, Inc | Compositions including il-18 and il-22 and their use in anti-viral therapies |
| MX2017010919A (es) | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
| JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、ｒｎａ含有組成物 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| WO2017136818A2 (en) | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| ITUA20161992A1 (it) | 2016-03-24 | 2017-09-24 | Plico Biotech Inc | Sumo e suoi utilizzi |
| WO2018027155A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP3519436A4 (en) | 2016-09-30 | 2020-09-09 | Baylor College of Medicine | TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY |
| TWI591177B (zh) | 2016-10-27 | 2017-07-11 | 中化合成生技股份有限公司 | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 |
| KR102739572B1 (ko) | 2017-03-06 | 2024-12-10 | 알토 바이오사이언스 엘엘씨 | Il-12 및 il-18로의 il-15-기반 융합 |
| AU2018297248A1 (en) | 2017-07-03 | 2020-02-20 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
| JP2021521877A (ja) | 2018-05-04 | 2021-08-30 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ | 宿主細胞タンパク質のレベルが低減した組換えタンパク質の生産 |
| CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| AU2019328575B2 (en) | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| JP2022518144A (ja) | 2019-01-04 | 2022-03-14 | レパトワー イミューン メディシンズ， インコーポレイテッド | 高多様性ペプチドライブラリーを生成する方法およびタンパク質折り畳みを促進する方法 |
| JP7754723B2 (ja) | 2019-05-14 | 2025-10-15 | ウェアウルフ セラピューティクス， インコーポレイテッド | 分離部分及びその使用方法 |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| EP3976068A4 (en) | 2019-05-31 | 2023-08-09 | Children's National Medical Center | CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION |
| CA3150818A1 (en) | 2019-08-13 | 2021-02-18 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| CA3154771A1 (en) | 2019-10-09 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cytotoxic t cell resistant tumors |
| US20220047677A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc. | Immune cell function |
| US20220056091A1 (en) | 2020-08-19 | 2022-02-24 | Bright Peak Therapeutics Ag | Modified il-18 polypeptides and uses thereof |
| KR20230117120A (ko) | 2020-11-02 | 2023-08-07 | 심카 아이엘-18, 인크. | 인터류킨-18 변이체 및 사용 방법 |
| US20240197880A1 (en) | 2021-04-30 | 2024-06-20 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| WO2022260968A1 (en) | 2021-06-10 | 2022-12-15 | Chimera Bioengineering, Inc. | Compositions and methods for activating natural killer cells |
-
2018
- 2018-09-06 KR KR1020207009724A patent/KR20200066623A/ko not_active Ceased
- 2018-09-06 AU AU2018330444A patent/AU2018330444B2/en active Active
- 2018-09-06 IL IL305370A patent/IL305370A/en unknown
- 2018-09-06 JP JP2020513648A patent/JP2020533301A/ja active Pending
- 2018-09-06 CN CN201880071694.4A patent/CN111315395A/zh active Pending
- 2018-09-06 EP EP18853870.6A patent/EP3678681A4/en active Pending
- 2018-09-06 WO PCT/US2018/049648 patent/WO2019051015A1/en not_active Ceased
- 2018-09-06 BR BR112020004389-3A patent/BR112020004389A2/pt unknown
- 2018-09-06 IL IL272635A patent/IL272635B2/en unknown
- 2018-09-06 MX MX2020002542A patent/MX2020002542A/es unknown
- 2018-09-06 CA CA3080492A patent/CA3080492A1/en active Pending
- 2018-09-06 SG SG11202001384TA patent/SG11202001384TA/en unknown
- 2018-09-06 US US16/123,063 patent/US20190070262A1/en not_active Abandoned
-
2022
- 2022-11-15 US US18/055,581 patent/US12343379B2/en active Active
-
2023
- 2023-01-20 US US18/157,385 patent/US20230321192A1/en active Pending
- 2023-03-08 US US18/180,389 patent/US12403180B2/en active Active
- 2023-07-19 ZA ZA2023/07212A patent/ZA202307212B/en unknown
- 2023-08-18 JP JP2023133442A patent/JP2023157959A/ja active Pending
- 2023-11-15 AU AU2023266285A patent/AU2023266285A1/en not_active Abandoned
-
2024
- 2024-04-04 US US18/626,930 patent/US20240325494A1/en active Pending
- 2024-11-08 US US18/941,441 patent/US20250057918A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL272635B2 (en) | 2024-02-01 |
| ZA202307212B (en) | 2024-10-30 |
| JP2020533301A (ja) | 2020-11-19 |
| JP2023157959A (ja) | 2023-10-26 |
| KR20200066623A (ko) | 2020-06-10 |
| US20190070262A1 (en) | 2019-03-07 |
| RU2020112538A3 (OSRAM) | 2022-04-04 |
| EP3678681A4 (en) | 2021-07-14 |
| IL272635A (en) | 2020-03-31 |
| US20230241172A1 (en) | 2023-08-03 |
| US20240325494A1 (en) | 2024-10-03 |
| AU2018330444A1 (en) | 2020-04-23 |
| CA3080492A1 (en) | 2019-03-14 |
| IL272635B1 (en) | 2023-10-01 |
| US20230321192A1 (en) | 2023-10-12 |
| AU2018330444B2 (en) | 2023-08-17 |
| US12403180B2 (en) | 2025-09-02 |
| SG11202001384TA (en) | 2020-03-30 |
| CN111315395A (zh) | 2020-06-19 |
| AU2023266285A1 (en) | 2024-01-25 |
| US20250057918A1 (en) | 2025-02-20 |
| US12343379B2 (en) | 2025-07-01 |
| US20230355714A1 (en) | 2023-11-09 |
| IL305370A (en) | 2023-10-01 |
| WO2019051015A1 (en) | 2019-03-14 |
| RU2020112538A (ru) | 2021-10-06 |
| MX2020002542A (es) | 2020-07-20 |
| EP3678681A1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12403180B2 (en) | Interleukin-18 variants and methods of use | |
| US11850276B2 (en) | Interleukin-18 variants and methods of use | |
| US12029778B2 (en) | Interleukin-18 mimics and methods of use | |
| CN112566661B (zh) | 喹啉衍生物与抗体的药物组合 | |
| US20150266967A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| US20240342246A1 (en) | Interleukin-12 variants and methods of use | |
| RU2797536C2 (ru) | Варианты интерлейкина-18 и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |